-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ARt8ZR9g6OsghqJXckNEwXMndRN9btYh2juxN198QudVZH5feMU7gQuI69Fz7MMJ HrbUdd691FR5oJ7JdSa57A== 0001341004-07-001671.txt : 20070828 0001341004-07-001671.hdr.sgml : 20070828 20070522172822 ACCESSION NUMBER: 0001341004-07-001671 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 CORRESP 1 filename1.htm

[Regeneron Pharmaceuticals, Inc. Letterhead]

 

 

May 22, 2007

 

 

BY EDGAR AND FACSIMILE

 

Mr. Jim B. Rosenberg

Senior Assistant Chief Accountant

Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 6010

100 F Street, NE

Washington, D.C. 20549

 

 

RE:

Regeneron Pharmaceuticals, Inc.

 

 

Form 10-K for the fiscal year ended December 31, 2006

 

 

File No. 000-19034

 

Dear Mr. Rosenberg:

 

We are in receipt of your letter dated May 10, 2007 to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. regarding the above-referenced annual report on Form 10-K. We are in the process of finalizing a letter responding to your comments and will send it to you on or before May 31, 2007.

 

 

Sincerely,

 

 

 

/s/ Stuart Kolinski

 

 

 

Stuart Kolinski

 

Senior Vice President & General Counsel

 

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----